信迪利单抗联合DPF方案治疗Ⅱ/Ⅲ期食管鳞状细胞癌的疗效观察  

Observation of the Effect of Xindilizumab Combined with DPF Regimen in the Treatment of StageⅡ/ⅢEsophageal Squamous Cell Carcinoma

作　　者：郭喜喜[1] 胡红军[1] 展晖[1] 毛恺[1] GUO Xixi;HU Hongjun;ZHAN Hui(Xinxiang Central Hospital,Xinxiang,453000)

机构地区：[1]河南省新乡市中心医院,453000

出　　处：《实用癌症杂志》2024年第12期2008-2012,共5页The Practical Journal of Cancer

基　　金：吴阶平医学基金会临床科研专项资助基金项目(编号:320.6750.2021-02-125)。

摘　　要：目的探讨信迪利单抗联合DPF方案治疗Ⅱ/Ⅲ期食管鳞状细胞癌的疗效。方法依据随机数字表法将96例Ⅱ/Ⅲ期食管鳞状细胞癌患者分为对照组(n=48)和观察组(n=48)。对照组采用DPF方案治疗,观察组在对照组基础上联合信迪利单抗治疗,均持续治疗4个周期,并随访至2023年3月。比较两组临床疗效、血清肿瘤标志物、免疫功能、不良反应及生存情况。结果观察组临床缓解率长于对照组(P<0.05);治疗4个周期时,两组血清肿瘤标志物水平、免疫功能指标均较治疗前改善,且观察组血清肿瘤标志物水平、免疫功能指标改善优于对照组(P<0.05);两组治疗期间胃肠道反应、肝功能异常、骨髓抑制、甲状腺功能异常、蛋白尿、中性粒细胞减少等不良反应发生率比较,差异无统计学意义(P>0.05);随访至2023年3月,观察组平均生存时间长于对照组(P<0.05)。结论信迪利单抗联合DPF方案可提高Ⅱ/Ⅲ期食管鳞状细胞癌患者的治疗效果,降低血清肿瘤标志物水平,改善患者免疫功能,还可延长患者生存时间,且不会明显增加不良反应。Objective To explore the therapeutic effect of Xindilimab combined with DPF regimen in the treatment of stageⅡ/Ⅲesophageal squamous cell carcinoma.Methods According to the random number table method,96 patients with stageⅡ/Ⅲesophageal squamous cell carcinoma were divided into the control group(n=48)and the observation group(n=48).The control group was treated with the DPF regimen,while the observation group was treated with a combination of Xindilizumab on the basis of the control group.Both groups were continuously treated for 4 cycles and followed up until March 2023.The clinical efficacy,serum tumor markers,immune function,adeverse reactions,and survival were compared between the 2 groups.Results The clinical remission rate in the observation group was higher than that in the control group(P<0.05).After 4 cycles of treatment,the levels of serum tumor markers and immune function indicators in both groups improved compared to before treatment,and the observation group showed better improvement in serum tumor marker levels and immune function indicators than the control group(P<0.05).There was no statistical significant difference in the incidence of toxic side effects such as gastrointestinal reactions,liver dysfunction,bone marrow suppression,thyroid dysfunction,proteinuria,and neutropenia between the 2 treatment groups(P>0.05).Follow up until March 2023,the average survival time of the observation group was higher than that of the control group(P<0.05).Conclusion The combination of Xindilizumab and DPF regimen can improve the therapeutic effect of stageⅡ/Ⅲesophageal squamous cell carcinoma patients,reduce serum tumor marker levels,improve patient immune function,and prolong patient survival time without significantly increasing adverse reactions.

关 键 词：食管鳞状细胞癌 信迪利单抗 DPF方案 疗效 肿瘤标志物 

分 类 号：R735.1[医药卫生—肿瘤]